1 Introduction
Advances in focused remedy and immunotherapy have led to personalised remedy approaches for superior non-small cell lung most cancers (NSCLC) (1, 2). Specifically, the introduction of anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKIs) has remodeled the remedy prospects for sufferers with superior NSCLC, with ALK gene rearrangements, affording an goal response fee of 74% and extended survival (3, 4).
Proof from latest trials suggests the potential advantages of neoadjuvant or adjuvant focused remedy in early-stage illness (5, 6). Nevertheless, the position of ALK-TKIs in early-stage and domestically superior ALK-positive NSCLC has not been extensively analyzed. Sure retrospective research and small-scale, early-phase trials have reported glorious responses to the neoadjuvant use of ALK-TKIs (7–9).
Brigatinib, a second-generation ALK-TKI, has proven exceptional efficacy in treating superior ALK-positive NSCLC by overcoming crizotinib-resistant ALK mutations (10). Herein, we current, to the most effective of our information, the primary case report of a affected person attaining a pathologic full response (pCR) after brigatinib remedy within the neoadjuvant setting of stage III ALK-positive NSCLC. The current case not solely highlights the security and feasibility of surgical procedure following brigatinib remedy but in addition affords pathological proof of the potent antitumor efficacy of brigatinib.
2 Case description
A 32-year-old male with no comorbidities, a historical past of solely two pack-years of present smoking, and with out particular danger components, resembling a household historical past of lung most cancers, occupational publicity, or environmental publicity, visited a tertiary referral hospital for additional analysis of incidental lung nodules. The nodules had been found on a chest X-ray throughout a routine well being check-up in November 2022, and he didn’t exhibit any particular signs. Serum tumor marker evaluation revealed an elevated carcinoembryonic antigen (CEA) degree of 8.49 ng/ml (reference worth < 5 ng/ml). Nevertheless, routine blood chemistry and pulmonary perform checks confirmed no vital abnormalities.
3 Diagnostic evaluation
On chest computed tomography, two lobulated enhancing lung lesions, measuring 4.9 and 1.2 cm, had been recognized in the fitting decrease lobe, together with an enlarged proper interlobar lymph node (Figures 1A–C). No different vital findings had been famous on the computed tomography. Endobronchial ultrasound-guided transbronchial needle aspiration was carried out on the fitting decrease lobe mass. Histopathological examination of the biopsy specimen revealed adenocarcinoma with focal mucinous differentiation (Figures 2A, B). Throughout staging investigations, no proof of distant metastasis was noticed on the bone scan, mind magnetic resonance imaging, and positron emission tomography. In the end, the affected person was recognized with scientific stage T3N1M0, IIIA (American Joint Committee on Most cancers 8th version) on January 2, 2023 (11). Molecular testing utilizing each immunohistochemistry, with a monoclonal antibody (D5F3; Ventana-Roche Diagnostics, Mannheim, Germany), and fluorescent in situ hybridization (Vysis LSI ALK Break-Aside FISH Probe Equipment, Abbott Molecular Inc., Abbott Park, IL, USA) confirmed an ALK gene rearrangement (Figures 2C, D). After a multidisciplinary dialogue, the affected person determined to proceed with surgical procedure, after neoadjuvant brigatinib remedy. Brigatinib monotherapy was administered at a dose of 90 mg, as soon as every day for the primary 7 days. This was well-tolerated; the dose was subsequently elevated to 180 mg as soon as every day and continued. This remedy supplied a dramatic radiographic response, with a major discount within the major lung tumor measurement from 4.9 to 1.7 cm (Figures 1D–F). Upon re-evaluation of serum tumor markers, CEA was lowered to below-normal ranges, and there have been no abnormalities detected in different routine blood biochemistry checks. After 58 days of brigatinib remedy, video-assisted thoracoscopic proper decrease lobectomy with mediastinal lymph node dissection was carried out with healing intent. The surgical process was carried out with out issues, with no residual tumor detected on evaluation of intraoperative frozen sections. Histopathological examination of the resected specimen then confirmed a pCR, with no proof of viable tumor cells (Determine 3). The affected person continued remedy with brigatinib, and there was no proof of recurrence till the final follow-up, 13 months post-surgery. Moreover, the affected person didn’t expertise any brigatinib-related adversarial occasions, and there have been no notable findings in both the tumor marker or biochemistry laboratory take a look at outcomes. Determine 4 illustrates the timeline of the complete remedy course of.
Determine 1 Computed tomography pictures earlier than and after remedy with brigatinib. (A–C) Earlier than remedy, a major mass measuring 4.9 cm will be noticed, together with a satellite tv for pc nodule measuring 1.2 cm within the decrease lobe of the fitting lung, with proper interlobar lymph node metastasis. (D–F) A major response within the major lung lesions, satellite tv for pc nodule, and lymph node will be noticed after brigatinib remedy.
Determine 2 Pathological examination of the tissue specimen from endobronchial ultrasound-guided transbronchial needle aspiration and video-assisted thoracoscopic proper decrease lobectomy with mediastinal lymph node dissection. (A) The biopsy pattern exhibits clusters of atypical epithelial cells with plump cytoplasm (H&E, 200×). (B) Consultant immunohistochemistry picture displaying tumor cells nuclear-positive for TTF1 (200×). (C) Consultant picture displaying robust granular cytoplasmic expression of anaplastic lymphoma kinase (D5F3, Ventana CDx) (H&E, 200×). (D) Consultant picture displaying a break within the ALK locus, indicated by the Vysis ALK Break irregular sign sample of remoted crimson and distinct break-apart indicators (Vysis ALK Break Aside FISH probe).
Determine 3 (A) The low magnification view exhibits a nodular space, thought-about the tumor mattress (H&E, 10×). (B) Lymphoid aggregation and fibroblast will be noticed within the nodular space of (A) (H&E, 100×). (C) Fibrotic modifications will be seen within the peribronchial space, which is suitable with the tumor mattress (H&E, 400×). (D) Within the high-power view of (C), macrophage and lymphocyte infiltration and a ldl cholesterol cleft will be noticed within the fibrotic space. (H&E). Total, there are not any viable tumor cells on tumor mattress and the ultimate prognosis is suitable with pathologic full response.
Determine 4 The timeline of the complete remedy course of.
4 Dialogue
To the most effective of our information, the present case report represents the primary occasion of a affected person attaining a pCR after neoadjuvant brigatinib remedy for stage III ALK-positive NSCLC. This not solely highlights the security and feasibility of subsequent surgical intervention but in addition supplies sturdy pathological proof of the potent antitumor efficacy of brigatinib.
ALK-TKIs have markedly improved outcomes in sufferers with superior ALK-positive NSCLC, who account for two–7% of all NSCLC instances (4, 12). Historically, the remedy technique for early-stage ALK-positive NSCLC has been just like that for NSCLC with out oncogenic driver mutations, attaining a 5-year survival fee for stage IIIA NSCLC of solely 36% (1). Nevertheless, promising outcomes from latest functions of superior NSCLC therapies in early-stage, perioperative settings are shifting this paradigm (13). Furthermore, historic research have demonstrated encouraging responses to ALK-TKIs within the neoadjuvant setting, resulting in ongoing analysis, such because the ALNEO and NAUTICA1 trials (7–9, 14, 15). The outcomes of those research are promising and counsel potential modifications in remedy methods that might supply extra personalised choices for these sufferers. In Korea, reimbursement is supplied for using first-line ALK-TKIs, and neoadjuvant ALK-TKI remedy has been chosen by means of multidisciplinary session. Consequently, the implementation of complete molecular pathology testing may additional improve remedy efficacy in early-stage NSCLC (16).
A dramatic radiologic response to brigatinib remedy has been generally noticed in sufferers with superior ALK-positive NSCLC ( (10, 17). Based mostly on historic analyses, brigatinib is predicted to exert probably the most expansive vary of efficacy in opposition to ALK mutations, with encompassing exercise in opposition to secondary mutants predicted to confer excessive resistance to ceritinib or alectinib (18–20). Not too long ago, Zhang et al. reported the efficacy of alectinib in sufferers with N2 NSCLC, with 11 sufferers (91%) displaying a serious pathological response. Furthermore, two sufferers (18.2%) achieved a pCR (8). Moreover, Zenke et al. reported on the efficacy of ceritinib in sufferers with stage IIIA NSCLC, with 4 sufferers (57%) displaying a serious pathological response and two sufferers (28%) attaining a pCR (9). Nevertheless, no earlier case report has documented pathological proof of a pCR achieved with brigatinib remedy. The present case report means that neoadjuvant brigatinib is each efficient and secure in resectable stage III ALK-positive NSCLC.
A number of questions concerning using ALK-TKIs in early-stage NSCLC should be addressed. The period of neoadjuvant remedy and the optimum timing of surgical procedure stay unclear. Scientific trials are wanted to evaluate the security and efficacy of neoadjuvant remedy. Moreover, it must be established whether or not upkeep remedy with ALK-TKIs is efficient for sufferers with ALK-positive NSCLC who’ve proven favorable responses within the neoadjuvant setting.
5 Conclusion
In conclusion, we introduced a case of ALK-positive NSCLC with a pCR in resected specimens after remedy with brigatinib. Conversion surgical procedure after brigatinib remedy could also be secure and efficient in sufferers with ALK-positive NSCLC.
Information availability assertion
The unique contributions introduced within the research are included within the article supplies. Additional inquiries will be directed to the corresponding writer.
Ethics assertion
The research involving people had been authorized by Institutional Evaluate Board of Pusan Nationwide College Hospital (IRB no. 2310-017-131). The research had been performed in accordance with the native laws and institutional necessities. The contributors supplied their written knowledgeable consent to take part on this research. Written knowledgeable consent was obtained from the person(s) for the publication of any probably identifiable pictures or knowledge included on this article.
Writer contributions
HS: Writing – overview & modifying, Writing – authentic draft, Methodology, Conceptualization. SK: Writing – authentic draft, Validation, Information curation. MK: Writing – authentic draft, Supervision, Investigation. JC: Writing – overview & modifying, Supervision, Assets. AK: Writing – overview & modifying, Supervision, Assets. JE: Writing – overview & modifying.
Funding
The writer(s) declare monetary help was acquired for the analysis, authorship, and/or publication of this text. This work was supported by a scientific analysis grant from Pusan Nationwide College Hospital in 2024.
Battle of curiosity
The authors declare that the analysis was performed within the absence of any industrial or monetary relationships that may very well be construed as a possible battle of curiosity.
Writer’s word
All claims expressed on this article are solely these of the authors and don’t essentially signify these of their affiliated organizations, or these of the writer, the editors and the reviewers. Any product which may be evaluated on this article, or declare which may be made by its producer, isn’t assured or endorsed by the writer.
References
1. Ettinger DS, Wooden DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN tips® Insights: non–small cell lung most cancers, model 2.2023: featured updates to the NCCN tips. J Natl Compr Canc Netw. (2023) 21:340–50. doi: 10.6004/jnccn.2023.0020
PubMed Summary | CrossRef Full Textual content | Google Scholar
2. Li S, de Camargo Correia GS, Wang J, Manochakian R, Zhao Y, Lou Y. Rising focused therapies in superior non-small-cell lung most cancers. Cancers. (2023) 15:2899. doi: 10.3390/cancers15112899
PubMed Summary | CrossRef Full Textual content | Google Scholar
3. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa Ok, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung most cancers. N Engl J Med. (2014) 371:2167–77. doi: 10.1056/NEJMoa1408440
PubMed Summary | CrossRef Full Textual content | Google Scholar
4. Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. Up to date general survival and ultimate progression-free survival knowledge for sufferers with treatment-naive superior ALK-positive non-small-cell lung most cancers within the ALEX research. Ann Oncol. (2020) 31:1056–64. doi: 10.1016/j.annonc.2020.04.478
PubMed Summary | CrossRef Full Textual content | Google Scholar
5. Lv C, Fang W, Wu N, Jiao W, Xu S, Ma H, et al. Osimertinib as neoadjuvant remedy in sufferers with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label part 2b trial. Lung Most cancers. (2023) 178:151–6. doi: 10.1016/j.lungcan.2023.02.011
PubMed Summary | CrossRef Full Textual content | Google Scholar
6. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung most cancers. N Engl J Med. (2020) 383:1711–23. doi: 10.1056/NEJMoa2027071
PubMed Summary | CrossRef Full Textual content | Google Scholar
7. Zhang C, Li SL, Nie Q, Dong S, Shao Y, Yang XN, et al. Neoadjuvant crizotinib in resectablelocally superior non-small cell lung most cancers with ALK rearrangement. J Thorac Oncol. (2019) 14:726–31. doi: 10.1016/j.jtho.2018.10.161
PubMed Summary | CrossRef Full Textual content | Google Scholar
8. Zhang C, Yan LX, Jiang BY, Wu YL, Zhong WZ. Feasibility and security of neoadjuvant alectinib in a affected person with ALK-positive domestically superior NSCLC. J Thorac Oncol. (2020) 15:e95–9. doi: 10.1016/j.jtho.2019.12.133
PubMed Summary | CrossRef Full Textual content | Google Scholar
9. Zenke Y, Yoh Ok, Sakakibara-Konishi J, Daga H, Hosomi Y, Nogami N, et al. P1.18-04 neoadjuvant ceritinib for domestically superior non-small cell lung most cancers with ALK rearrangement: SAKULA trial. J Thorac Oncol. (2019) 14:S626–7. doi: 10.1016/j.jtho.2019.08.1320
10. Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Lee JS, et al. Brigatinib versus crizotinib in ALK-positive non–small-cell lung most cancers. N Engl J Med. (2018) 379:2027–39. doi: 10.1056/NEJMoa1810171
PubMed Summary | CrossRef Full Textual content | Google Scholar
12. Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung most cancers: Previous, current and future. World J Clin Oncol. (2021) 12:217–37. doi: 10.5306/wjco.v12.i4.217
PubMed Summary | CrossRef Full Textual content | Google Scholar
14. Leonetti A, Minari R, Boni L, Gnetti L, Verzè M, Ventura L, et al. Open-label, single-arm, multicenter research to evaluate the exercise and security of alectinib as neoadjuvant remedy in surgically resectable stage III ALK-positive NSCLC: ALNEO trial. Clin Lung Most cancers. (2021) 22:473–7. doi: 10.1016/j.cllc.2021.02.014
PubMed Summary | CrossRef Full Textual content | Google Scholar
15. López-Castro R, García-Peña T, Mielgo-Rubio X, Riudavets M, Teixidó C, Vilariño N, et al. Concentrating on molecular alterations in non-small-cell lung most cancers: what’s subsequent? Pers Med. (2022) 19:341–59. doi: 10.2217/pme-2021-0059
16. Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, et al. Molecular testing in stage I–III non-small cell lung most cancers: Approaches and challenges. Lung Most cancers. (2021) 162:42–53. doi: 10.1016/j.lungcan.2021.09.003
PubMed Summary | CrossRef Full Textual content | Google Scholar
17. Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, et al. Brigatinib versus Crizotinib in ALK inhibitor-naïve superior ALK-Constructive NSCLC: Closing outcomes of part 3 ALTA-1L Trial. J Thorac Oncol. (2021) 16:2091–108. doi: 10.1016/j.jtho.2021.07.035
PubMed Summary | CrossRef Full Textual content | Google Scholar
18. Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, et al. The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical fashions. Clin Most cancers Res. (2016) 22:5527–38. doi: 10.1158/1078-0432.CCR-16-0569
PubMed Summary | CrossRef Full Textual content | Google Scholar
19. Carcereny E, Fernández-Nistal A, López A, Montoto C, Naves A, Segú-Vergés C, et al. Face to face analysis of second era ALK inhibitors brigatinib and alectinib as first-line remedy for ALK+ NSCLC utilizing an in silico methods biology-based strategy. Oncotarget. (2021) 12:316–32. doi: 10.18632/oncotarget.v12i4
PubMed Summary | CrossRef Full Textual content | Google Scholar
20. Ali R, Arshad J, Palacio S, Mudad R. Brigatinib for ALK-positive metastatic non-small-cell lung most cancers: design, improvement and place in remedy. Drug Des Devel Ther. (2019) 13:569–80. doi: 10.2147/DDDT.S147499
PubMed Summary | CrossRef Full Textual content | Google Scholar
